Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis

[1] Szarvas T(2011)Matrix metalloproteinases and their clinical relevance in urinary bladder cancer Nat Rev Urol. 8 241-254

[2] vom Dorp F(2009)Targeting matrix metalloproteinases in inflammatory conditions Curr Drug Targets 10 1245-1254

[3] Ergün S(2010)Matrix metalloproteinases involvement in pathologic conditions Rom J Morphol Embryol 51 215-228

[4] Rübben H(2011)Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease Am J Nephrol 34 211-219

[5] Clutterbuck AL(2014)Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors Biochem Pharmacol 90 7-15

[6] Asplin KE(2007)Role of matrix metalloproteinases in renal pathophysiologies Am J Physiol Renal Physiol 292 F905-F911

[7] Harris P(2012)Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target Basic Clin Pharmacol Toxicol 110 409-415

[8] Allaway D(2009)Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease Circulation 120 792-801

[9] Mobasheri A(2014)A current understanding of vascular calcification in CKD Am J Physiol Renal Physiol 307 F891-F900

[10] Amălinei C(2002)Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 251-262

[1] Szarvas T(2011)Matrix metalloproteinases and their clinical relevance in urinary bladder cancer Nat Rev Urol. 8 241-254

[2] vom Dorp F(2009)Targeting matrix metalloproteinases in inflammatory conditions Curr Drug Targets 10 1245-1254

[3] Ergün S(2010)Matrix metalloproteinases involvement in pathologic conditions Rom J Morphol Embryol 51 215-228

[4] Rübben H(2011)Activation of arterial matrix metalloproteinases leads to vascular calcification in chronic kidney disease Am J Nephrol 34 211-219

[5] Clutterbuck AL(2014)Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors Biochem Pharmacol 90 7-15

[6] Asplin KE(2007)Role of matrix metalloproteinases in renal pathophysiologies Am J Physiol Renal Physiol 292 F905-F911

[7] Harris P(2012)Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target Basic Clin Pharmacol Toxicol 110 409-415

[8] Allaway D(2009)Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease Circulation 120 792-801

[9] Mobasheri A(2014)A current understanding of vascular calcification in CKD Am J Physiol Renal Physiol 307 F891-F900

[10] Amălinei C(2002)Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly Circ Res 90 251-262